AustinPx, a Contract Development and Manufacturing Organization (CDMO) based in Texas, has forged an exclusive agreement with Thermo Fisher Scientific’s Patheon division, a move set to significantly expand the commercial accessibility of AustinPx’s innovative KinetiSol technology. The collaboration, announced on June 30, 2026, involves the installation of KinetiSol Formulator units at Patheon’s state-of-the-art facilities in Bend, Oregon, and Cincinnati, Ohio. This strategic partnership aims to enhance bioavailability for orally delivered small molecules, a critical challenge in modern drug development, by integrating KinetiSol-enabled amorphous solid dispersion (ASD) capabilities across the entire drug lifecycle, from early development to large-scale commercial manufacturing. The integration with Patheon’s advanced Quadrant 2 platform, which leverages artificial intelligence and machine learning for formulation prediction, underscores a growing industry trend towards data-driven and technology-agnostic solutions for complex pharmaceutical challenges.
Addressing the Pervasive Challenge of Poor Drug Solubility
The pharmaceutical industry grapples with a persistent and widespread problem: poor drug solubility. According to a comprehensive 2023 review published in the journal Life, approximately 40% of currently commercialized drugs and a staggering 70% to 90% of drug candidates still undergoing development exhibit poor aqueous solubility. This inherent characteristic poses a significant hurdle to therapeutic efficacy, as a drug must dissolve in bodily fluids to be absorbed into the bloodstream and reach its target site. Poor solubility directly translates to low bioavailability, meaning only a fraction of the administered dose actually exerts a therapeutic effect. Consequently, formulators are often compelled to use higher doses to achieve desired outcomes, which can unfortunately lead to an increased incidence of dose-dependent side effects, diminished patient compliance, and elevated development costs. The need for advanced bioavailability enhancement technologies like KinetiSol is therefore not merely an incremental improvement but a fundamental requirement for unlocking the full therapeutic potential of a vast majority of drug candidates.
KinetiSol Technology: A Novel Approach to Amorphous Solid Dispersions
Amorphous solid dispersions (ASDs) represent a proven strategy to overcome poor drug solubility. By converting a crystalline active pharmaceutical ingredient (API) into an amorphous form and dispersing it within a polymer matrix, ASDs significantly increase the drug’s dissolution rate and, subsequently, its bioavailability. While established ASD techniques like hot-melt extrusion (HME) and spray drying have been widely utilized, they often come with specific limitations. KinetiSol, AustinPx’s proprietary technology, offers a differentiated approach. Unlike HME which relies on sustained high temperatures and specific polymer rheology, or spray drying which requires the API and polymer to be soluble in a common volatile solvent, KinetiSol utilizes a rapid, solvent-free, and high-energy input process. This method allows for the creation of stable amorphous dispersions even with APIs that are poorly soluble in organic solvents, possess high melting points, exhibit time-dependent thermal lability, or are sensitive to prolonged heat exposure. It also broadens the range of compatible polymers and excipients, enabling more complex multi-component ASD systems that can address specific formulation needs, such as pill-burden reduction, improved manufacturability, or modified release profiles. AustinPx has cultivated over 16 years of expertise in KinetiSol formulation and process development, scale-up, and technology transfer, positioning it as a leader in this specialized field.
Strategic Rationale: Expanding Commercial Access and De-risking Development
The decision by AustinPx to route commercial-scale access through an external CDMO like Patheon, rather than solely building out in-house capacity, reflects a shrewd strategic calculus. Elizabeth Hickman, CEO of AustinPx, emphasized that this agreement with Thermo Fisher Scientific, one of the largest CDMOs in the industry, is a strong validation of the growing demand for differentiated amorphous dispersion technologies. While AustinPx will continue to offer its comprehensive KinetiSol capabilities, including Formulator services, to its extensive client base (over 80 clients in the last four years), the partnership expands the broader KinetiSol commercial ecosystem.
"KinetiSol was built for scale," Hickman stated, highlighting AustinPx’s prior experience in supporting technology transfers, commercial-scale equipment installations, and registration-scale manufacturing programs. As drug development programs progress towards Phase 3 and commercialization, sponsors critically need confidence in the scalability, reliability, and transferability of formulation processes. Partnering with a global leader like Patheon provides this crucial assurance. It offers sponsors increased capacity, additional CDMO optionality, and significantly enhanced commercial confidence for their KinetiSol-enabled products. Alongside existing partners like Microsize, Thermo Fisher Scientific now provides another robust access point for late-stage and commercial manufacturing.
For clients, this agreement unlocks a crucial element: greater confidence in the downstream commercialization path for KinetiSol-enabled products. Historically, specialized technologies might have been perceived as niche or "last-resort" options. However, with Patheon’s endorsement and integration, KinetiSol can now be considered a scalable, commercially relevant pathway for challenging molecules from the outset. This shift in perception is vital in the heavily regulated pharmaceutical industry, where sponsors are inherently cautious about committing to enabling technologies without a clear and credible path from early development through late-stage clinical trials and into commercial manufacturing. The partnership effectively de-risks the long-term viability of KinetiSol-based formulations, encouraging earlier adoption and potentially streamlining development timelines.
Thermo Fisher Patheon’s Strategic Imperative: Enhancing Portfolio and Predictive Capabilities
For Thermo Fisher Scientific’s Patheon division, the exclusive agreement represents a significant enhancement to its comprehensive service portfolio. As a leading global CDMO, Patheon continuously seeks to integrate cutting-edge technologies to meet the evolving needs of its pharmaceutical and biotech clients. The addition of KinetiSol not only expands Patheon’s capabilities in bioavailability enhancement—a critical area given the prevalence of poorly soluble compounds—but also strengthens its competitive position in the highly specialized ASD market.
The strategic placement of KinetiSol at Patheon’s Bend, Oregon, and Cincinnati sites is particularly noteworthy. These facilities are known for their advanced capabilities in formulation development and manufacturing. Furthermore, the integration with Patheon’s proprietary Quadrant 2 predictive platform signifies a forward-thinking approach. Quadrant 2 leverages artificial intelligence and machine learning to predict optimal drug formulations, thereby accelerating development cycles, reducing the need for extensive experimental work, and conserving valuable API. By incorporating KinetiSol process and formulation data into this AI/ML model, Patheon can refine its predictive algorithms, leading to more accurate and efficient formulation strategies. A larger, richer KinetiSol dataset within Quadrant 2 will undoubtedly enhance the platform’s predictive power over time, enabling scientists to make more informed decisions earlier in the development process, avoid unproductive experiments, and proactively identify potential risks. This synergy between advanced formulation technology and predictive analytics positions Patheon at the forefront of pharmaceutical development innovation.
KinetiSol’s Differentiated Advantages and Expanding Use Cases
When formulation scientists weigh options for amorphous solid dispersions, KinetiSol presents compelling advantages, particularly for molecules that pose challenges for traditional methods. As Elizabeth Hickman articulated, "One size does not fit all in ASD development." The choice of technology must align with both the molecule’s intrinsic characteristics and the overall product strategy, considering factors like performance, scalability, manufacturability, sustainability, and long-term value.
KinetiSol shines when APIs exhibit:
- Poor solubility in organic solvents: A common limitation for spray drying.
- High melting points: Which can make hot-melt extrusion difficult or require excessive temperatures.
- Time-dependent thermal lability or heat sensitivity: KinetiSol’s rapid, localized heating minimizes overall thermal exposure compared to the sustained heat of HME.
- Incompatibility with common polymers/excipients: KinetiSol’s broader formulation design space allows for a wider selection.
- Need for complex multi-component ASD systems: Beyond simple drug-polymer approaches.
Beyond these technical advantages, KinetiSol offers strategic benefits such as:
- Pill-burden reduction: Enabling higher drug loading.
- Improved manufacturability and cost reduction: Through an efficient, solvent-free process.
- Environmental improvements: As a greener manufacturing alternative due to the absence of organic solvents.
- Modified or targeted release profiles: Expanding therapeutic possibilities.
- Strengthening drug product intellectual property (IP): By offering a unique and differentiated formulation approach.
By encouraging sponsors to evaluate KinetiSol earlier in development, AustinPx and Patheon aim to capitalize on these benefits from the outset, leading to a lower-risk, higher-value development path.
Shifting Paradigms: From Last Resort to First Choice
Historically, many pharmaceutical sponsors would first attempt to formulate poorly soluble drugs using the more established ASD technologies like spray drying or hot-melt extrusion. KinetiSol, being a newer and more specialized technology, was sometimes reserved for molecules that had already failed with conventional methods or presented significant solvent, thermal, or scale-up limitations. This "last resort" perception, however, is rapidly changing.
Hickman notes that KinetiSol is increasingly becoming a first-choice technology for sponsors dealing with challenging molecules. This shift is driven by the technology’s demonstrated ability to deliver superior performance, scalability, sustainability, and a broader formulation design space. The partnership with Thermo Fisher Scientific significantly accelerates this paradigm shift. By providing another clearly defined and highly credible pathway for KinetiSol-enabled products moving into late-stage clinical testing and commercial manufacturing, the agreement reinforces industry confidence in KinetiSol as a high-performance, scalable, and commercially relevant ASD technology. The molecule’s characteristics remain the primary driver for technology selection, but this collaboration makes it considerably easier for sponsors to evaluate and adopt KinetiSol earlier, precisely when formulation decisions can have the most profound impact on a drug’s success.
Broader Implications for the Pharmaceutical Landscape
This exclusive agreement between AustinPx and Thermo Fisher Patheon is indicative of several broader trends shaping the pharmaceutical industry. Firstly, it highlights the increasing importance of strategic partnerships between specialized technology innovators and large-scale CDMOs. Such collaborations allow smaller, agile companies to gain broader market access and validation, while enabling global CDMOs to expand their technological offerings and cater to an increasingly complex drug pipeline. Secondly, it underscores the critical role of advanced formulation technologies in bringing challenging new chemical entities (NCEs) to market. As drug discovery moves towards more complex molecular structures, the need for sophisticated bioavailability enhancement solutions will only intensify. Finally, the integration of KinetiSol with Patheon’s AI/ML platform exemplifies the growing convergence of digital technologies and traditional pharmaceutical manufacturing. Data-driven approaches are becoming indispensable for accelerating development, optimizing processes, and ultimately, delivering safer and more effective medicines to patients faster.
The pharmaceutical CDMO market itself is a robust and growing sector, valued at hundreds of billions of dollars globally and projected to continue expanding significantly. Within this market, specialized services like bioavailability enhancement command premium value due to their critical impact on drug development success. The KinetiSol agreement positions both AustinPx and Patheon to capture a larger share of this growing demand, while offering substantial benefits to pharmaceutical companies striving to overcome solubility challenges and accelerate their drug candidates through the development pipeline. This collaboration marks a pivotal moment for KinetiSol, signaling its maturation from a specialized tool to a mainstream, commercially validated solution within the pharmaceutical industry’s arsenal for drug development.
